MAM
Disha Patani is Myntra’s first-ever beauty brand ambassador
NEW DELHI: Ahead of the festive season, Myntra announces Bollywood actress, Disha Patani, as its brand ambassador to further consolidate its strong position in the massive and rapidly-growing beauty and personal care (BPC) market in India. Disha has made her mark as a household name after captivating the nation with some awe-inspiring performances both in Bollywood and International cinema. Her interactive social media presence, coupled with her dashing style quotient, will help Myntra penetrate wider geographies while driving recall for the category at scale.
Myntra has about 400 brands and over 14,000 products in the beauty and personal care category, across makeup, fragrance, hair, grooming & appliances, skin, bath and body, making it an integral part of the overall style portfolio. The category is loaded with authentic products from the best of brands and enjoys a high repeat ratio from customers. Myntra’s unique proposition of offering a holistic range of curated fashion and lifestyle products has given a boost to cross-selling between categories among its consumers, further driving its dominance in the BPC space.
Disha’s upcoming, first-ever, brand campaign for the category will further emphasise the distinct value proposition of the company being a leading fashion and lifestyle destination for an entire gamut of products. Her pan-India appeal will bring to the table a holistic representation of a tech-savvy, modern-day celebrity with the appeal to connect and engage with countless enthusiasts for beauty and personal care products across various age-groups.
Disha said, “Beauty is an integral part of my life, even more since I became a model. Myntra has consistently pioneered the path to self-expression through fashion and beauty for fashion-forward customers, including myself. Through this association with Myntra, I hope to inspire and help people across India on their journey towards discovering their own unique fashion styles and preferences.”
Myntra CEO Amar Nagaram said, “In a first-ever for Myntra, this association with Disha as our beauty brand ambassador represents our increasing focus on the booming Beauty and Personal Care segment. Through our tech-based personalization capabilities, a growing portfolio, and content innovation, we are extending our superlative consumer experience to cater to the beauty needs of consumers and help them complete the look. Disha joins our illustrious list of celebrity brand ambassadors ahead of the festive season and will help us in our vision of providing a holistic fashion and lifestyle offering to our fashion-forward consumers across the nation under one roof.”
Myntra Studio, a unique influencer led proposition, for fashion and lifestyle, helps Myntra keep high customer engagement. Myntra Studio’s 600+ influencers showcase the latest trends from the world of fashion, including beauty hacks and makeup tips. This unparalleled content-led personalisation feature, driven by influencers, has helped Myntra build brand salience and trust among its customers.
Disha has nearly 40 million followers on Instagram alone, and she will be a key driver of trends and styles in the beauty and personal care space for Myntra.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
